Description

DX600 is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-anti-virus–C141H185N35O40S2—-[1]Yousif MH, et al. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res. 2012 Sep;66(3):269-75.|[2] Svilenov HL, et al. Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. Commun Biol. 2023 Apr 8;6(1):386.|[3]Joshi S, et al. Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur J Pharmacol. 2016 Mar 5;774:25-33.|[4]Fraga-Silva RA, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010 May-Jun;16(5-6):210-5. |[5]Liao K, et al. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).J Immunol Methods. 2013 Mar 29;389(1-2):52-60.–478188-26-0–3074.33–99.24–O=C(C1([H])N(CCC1)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C2([H])N(CCC2)C([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC3=O)CC4=CNC5=CC=CC=C45)=O)CCCCN)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC6=CC=C(C=C6)O)C(N7[C@@H](CCC7)C(N[C@@H](CC(O)=O)C(N8[C@@H](CCC8)C(N[C@@H](CCC(O)=O)C(NCC(NCC(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@H](CC(O)=O)NC(CNC(C)=O)=O)=O)CC9=CC=C(C=C9)O)=O)=O)CC=CN=CN)=O)=O)CO)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC=CC=C(C=C)O)=O)CC=CC=C(C=C)O)=O)N[C@H]3CC=CNC=CC=CC=C–Cardiovascular Disease–H2O : 50 mg/mL (ultrasonic)–Angiotensin-converting Enzyme (ACE)—-Metabolic Enzyme/Protease–Peptides